Could a single pill replace a cocktail of Anti-Rejection drugs after liver transplant?
NCT ID NCT06280950
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether liver transplant patients can safely switch from a standard anti-rejection drug (tacrolimus) to a different drug (everolimus) to protect their kidneys. About 340 adults who received their first liver transplant will be followed for 18-20 months. The goal is to see if this change keeps the liver healthy while reducing kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus
What this could lead to
If successful, this could allow liver transplant patients to take fewer anti-rejection drugs, reducing kidney damage and simplifying their medication routine.
What could go wrong
This is an early phase 2 trial with 340 participants, so results may not apply to everyone. There is a risk of organ rejection or side effects from changing medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor Medical Center (Site #: 71153)
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
Contact
-
Duke University Medical Center (Site #: 71139)
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icahn School of Medicine at Mount Sinai (Site #: 71115)
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic Hospital Arizona (Site #: 71144)
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
Contact Email: •••••@•••••
-
Northwestern University (Site #: 71110)
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco (Site #: 71108)
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pennsylvania (Site #: 71111)
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center (Site #: 71170)
RECRUITINGPittsburgh, Pennsylvania, 15260, United States
Contact Email: •••••@•••••
Contact